Pharma stock under pressure: Nektar Therapeutics (NASDAQ: NKTR)
Nektar Therapeutics (NASDAQ: NKTR) stock fell over 9.9% (Oct 7th-11th, 2019; Finviz) after Goldman Sachs analyst Paul Choi downgraded the company. Choi has cut his…
Nektar Therapeutics (NASDAQ: NKTR) stock fell over 9.9% (Oct 7th-11th, 2019; Finviz) after Goldman Sachs analyst Paul Choi downgraded the company. Choi has cut his…
Nektar Therapeutics (NASDAQ: NKTR) stock fell over 0.4% in the pre-market session on May 11th, 2018 on mixed first quarter of 2018 performance. The group…
Nektar Therapeutics Ltd (NASDAQ: NKTR) reported that the Phase 3 efficacy study of the drug NKTR-181 indicated the new chemical entity (NCE) that is the…